Results 141 to 150 of about 25,638 (254)

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome. [PDF]

Med Sci (Basel)
Ravić MP, Srejović IM, Andjić MM, Murić MD, Sretenović JZ, Jeremić NS, Milosavljević IM, Vuletić ML, Murić NN, Ravić KR, Bolevich SB, Sergeeva SP, Gorbunov AA, Bolevich SS, Jakovljević VL, Novaković JN.   +15 more
europepmc   +1 more source

Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review

The FEBS Journal, EarlyView.
This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas, Lucas Vinícius Souza Santos, André Gustavo Carvalho de Oliveira, Marina dos Santos Barreto, Deise Maria Rego Rodrigues Silva, Pedro Henrique Macedo Moura, Eloia Emanuelly Dias Silva, Ronaldy Santana Santos, Lucas Alves da Mota Santana, Rajiv Gandhi Gopalsamy, Adriana Gibara Guimarães, Lysandro Pinto Borges   +11 more
wiley   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Banerjee I, Krissheeven M, Pandey N, Banerjee S, Robinson J, Banerjee I.   +5 more
europepmc   +1 more source

Trends in GLP‐1‐Based Therapy Use Before and After Pregnancy

Diabetes, Obesity and Metabolism, EarlyView.
Nansi S. Boghossian, Lauren McAbee, Antonio F. Saad, Maged M. Costantine, Marwan Ma'ayeh, Joseph A. Ewing   +5 more
wiley   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing. [PDF]

Invest Ophthalmol Vis Sci
Liu X, Lin H, Shao Y, Shen J, Bi Y.
europepmc   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes

Journal of Diabetes Investigation, EarlyView.
In Japanese patients with diabetes undergoing colonoscopy, GLP‐1RA use was associated with a higher rate of inadequate bowel preparation after propensity score matching. Weekly formulations showed a higher rate than daily formulations, while additional adjusted analyses were directionally consistent but not statistically significant.
Osamu Ogawa
wiley   +1 more source

Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan. [PDF]

Endocrinol Diabetes Metab
Tu ST, Chiu CF, Chou CK, Chuang HH, Hu SW, Ko WC, Lee CY, Lin WY, Sung YJ, Tzeng TF, Wang W, Wu HF, Yeung CY, Chen B, Sim CJ, Huang KC.   +15 more
europepmc   +1 more source